Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan PHP for Unresectable Liver Cancer
NCT00096083Phase 2Completed
- Sponsor
- Delcath Systems
- Start
- Sep 2004
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of melphalan in hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), Neuroendocrine Neoplasm (NEN), Ocular melanoma (OM), cutaneous melanoma (CM), sponsored by Delcath Systems. Started Sep 2004; status: completed.
02
Drugs
melphalan
03
Conditions
hepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)Neuroendocrine Neoplasm (NEN)Ocular melanoma (OM)cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT00096083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096083.